Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PCC0208017 is an inhibitor of MARK3 and MARK4 with IC50s of 1.8 and 2.01 nM. PCC0208017 disrupts microtubule dynamics and displays potent antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 116.00 | |
2 mg | In stock | $ 169.00 | |
5 mg | In stock | $ 289.00 | |
10 mg | In stock | $ 478.00 | |
25 mg | In stock | $ 789.00 | |
50 mg | In stock | $ 1,080.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 318.00 |
Description | PCC0208017 is an inhibitor of MARK3 and MARK4 with IC50s of 1.8 and 2.01 nM. PCC0208017 disrupts microtubule dynamics and displays potent antitumor activity. |
In vitro | PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 (1-5 μM) decreases the phosphorylation of Tau. PCC0208017 (3-21 μM) suppresses the proliferation of glioma cells[1]. |
In vivo | In C57BL/6 mice bearing murine glioma GL261 xenograft tumor, PCC0208017 (50 and 100 mg/kg; oral) dose-dependently inhibits the growth of xenograft tumors derived with inhibition rates of 56.15% and 70.32%, respectively. PCC0208017 (50 mg/kg; oral) exhibits Cmax and Tmax of 1.36 μg/mL and 0.833 h in plasma and 0.14 μg/mL and 0.833 h in brain[1]. Co-treatment of PCC0208017 (50 mg/kg) significantly enhances the anti-tumor activity of Temozolomide (100 mg/kg) with inhibition rates from 34.15% to 83.5%[1]. |
Molecular Weight | 403.4 |
Formula | C19H20F3N7 |
CAS No. | 2623158-64-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (278.9 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PCC0208017 2623158-64-3 Apoptosis PCC-0208017 PCC 0208017 inhibitor inhibit